Kilitch Drugs (India)NSE:KILITCH +4.50%83 Quick Ratio is 1.73 as of Mar. 2026, which is 14% below its 10-year median of 2.00. GuruFocus rates NSE:KILITCH with a GF Score™ of 83/100 and a GF Value™ of ₹225.67 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Kilitch Drugs (India) ranks better than 58.19% on this metric.
Kilitch Drugs (India) has a quick ratio of 1.73. It generally indicates good short-term financial strength.
The historical rank and industry rank for Kilitch Drugs (India)'s Quick Ratio or its related term are showing as below:
NSE:KILITCH'
s Quick Ratio Range Over the Past 10 Years
Min: 1.05 Med: 2 Max: 4.03
Current: 1.73
During the past 13 years, Kilitch Drugs (India)'s highest Quick Ratio was 4.03. The lowest was 1.05. And the median was 2.00.
NSE:KILITCH's Quick Ratio is ranked better than 58.19% of 995
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs NSE:KILITCH: 1.73
Kilitch Drugs (India) (NSE:KILITCH) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Kilitch Drugs (India) Quick Ratio Related Terms
Kilitch Drugs (India) Quick Ratio Historical Data
* Premium members only.
The historical data trend for Kilitch Drugs (India)'s Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kilitch Drugs (India) Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Quick Ratio distribution charts can be found below:
* The bar in red indicates where Kilitch Drugs (India)'s Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Kilitch Drugs (India)'s Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kilitch Drugs (India) (NSE:KILITCH) has a Quick Ratio of 1.73 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Kilitch Drugs (India) and its competitors. This is 14% below median its historical median of 2.00. Over the past decade, Kilitch Drugs (India)'s Quick Ratio has ranged from 1.05 to 4.03. According to the industry distribution chart, Kilitch Drugs (India) ranks #416 out of 995 companies in the Drug Manufacturers industry, placing it in the top 41.8%.
Is Kilitch Drugs (India)'s Quick Ratio too high?
Kilitch Drugs (India)'s current Quick Ratio of 1.73 is 14% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 4.03. The Drug Manufacturers industry median Quick Ratio is 1.45. Kilitch Drugs (India)'s value of 1.73 is 19.3% above this industry median. Based on the distribution chart, Kilitch Drugs (India) ranks #416 out of 995 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kilitch Drugs (India) has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kilitch Drugs (India) ranks #416 out of 995 companies for Quick Ratio. This puts Kilitch Drugs (India) in the upper half of its industry. The industry median Quick Ratio is 1.45. Kilitch Drugs (India)'s value of 1.73 is 19.3% above this benchmark. Historically, Kilitch Drugs (India)'s own Quick Ratio has ranged from 1.05 to 4.03 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 1.45, Kilitch Drugs (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kilitch Drugs (India)'s current Quick Ratio of 1.73 is 19.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Kilitch Drugs (India) and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kilitch Drugs (India)'s current Quick Ratio is 1.73, which is 14% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹225.67, compared to a current price of ₹194.73 — trading 13.7% below its estimated fair value. The current Quick Ratio is 1.73, which is 14% below median its 10-year median of 2.00 and 19.3% above the Drug Manufacturers industry median of 1.45. Kilitch Drugs (India)'s overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Quick Ratio is 1.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?
Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued.
The current stock price of ₹194.73 is trading 13.7% below its estimated GF Value™ of ₹225.67.
GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.
Key valuation signals for NSE:KILITCH:
Quick Ratio: 1.73 (14% below median its 10-year median of 2.00)
GF Value™: ₹225.67 vs. price of ₹194.73 (13.7% below fair value)
Industry Position: 19.3% above the Drug Manufacturers median (#416 of 995)
No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
83GF Score
Get the complete analysis for NSE:KILITCH
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KILITCH has been successfully added to your 
